Brief: Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310
21/11/2024 10:45
Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O :
* LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRST
COHORT IN
PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS, ADVANCING TO
NEXT DOSE GROUP
* LIPELLA PHARMACEUTICALS INC - TRIAL EXPECTED TO CONCLUDE
BY
MID-2025 WITH TOP-LINE DATA BY YEAR-END 2024
Source text: ID:nGNX6JCkwl
Further company coverage: LIPO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group